A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways
← catalyst calendarSponsored by Biogen (industry) · BIIB — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
404actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-02 | actual | When the study began enrolling |
| Primary completion | 2026-03-10 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-10 | actual | The whole study's end, after follow-up |
| First posted | 2024-12-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteer
Interventions
- Drug: Litifilimab — also filed as BIIB059
- Device: AI
- Device: OBI
- Device: PFS
Primary outcomes
what the primary-completion date above is the date OFPart 1 and 2: Maximum Observed Concentration (Cmax) of Litifilimab
measured Pre-dose and at multiple timepoints up to Week 22
Part 1 and 2: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf)
measured Pre-dose and at multiple timepoints up to Week 22
Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed